Wassil Jim, COO, reported an open-market or private sale at Vaxcyte, Inc. involving 5915.000000 shares for an estimated $432214.97. Reported holdings after the transaction were 157016.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
CHIEF OPERATING OFFICER
Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as…
Represents RSUs issued in lieu of a cash bonus by election of the Reporting Person, such election available to all of Issuer's senior management. The RSUs are fully vested upon the date of grant.
Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024.
The price reported is a weighted-average price. The shares were sold at prices ranging from $72.50 to $73.47. The reporting person will provide upon request to the SEC, the issuer or security holder o…
issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $73.51 to $74.41. The reporting person will provide upon request to the SEC, the issuer or security holder o…
1/48 of shares subject to the option vest on March 27, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
Option is fully vested and exercisable.
0 other filings
0 recent txs